Key Predictors of Sexual Distress in Female Cancer Survivors ID 1252

INTRODUCTION: The rate of female sexual dysfunction (FSD) in cancer survivors is increasing due to improved survivorship, yet this quality-of-life metric is underreported, and predictors are understudied. We sought to identify predictors of high sexual distress in cancer patients seeking treatment in a sexual survivorship program. METHODS: Demographic, clinical, and sexual morbidity outcomes were compared between patients with and without clinically diagnosable FSD, as defined by Female Sexual Distress Scale (FSDS) scores ≥11. One-way ANOVA and t-tests assessed associations among variables. Significant predictors were entered into a linear regression model to evaluate the effect of cancer history and symptomatology on sexual morbidity outcomes. RESULTS: Of 284 patients, 84% (n=234) met criteria for FSD. Breast (75%), gynecologic (11%), hematologic (6%), and gastrointestinal (4%) cancers were the most common diagnoses. The regression model (F(9,n)=X, P <.001) showed that endocrine therapy receipt was associated with significantly higher FSDS scores (B=5.113, P =.015). Those with painful sex (B=7.248, P =.003), and problems with orgasm (B=8.554, P =.013) had higher FSDS scores. Age at diagnosis, primary language, menopausal status, relationship status, chemo receipt, and low desire were not significant predictors. CONCLUSIONS/IMPLICATIONS: Endocrine therapy, painful sex, and orgasm difficulties are strong predictors of greater sexual distress in female cancer survivors. These findings underscore the importance of addressing sexual health concerns early in cancer survivorship care, particularly for patients with estrogen-sensitive cancers who will be prescribed endocrine therapy. Future research should explore interventions specifically tailored to key predictors to improve sexual health outcomes in this population.